World, European and German pharmaceutical markets

 

World, European and German pharmaceutical markets

Abr.: WM = world market; EU = European market; US = US market; D = German market

world pharmaceutical market (in US$ bn)

Year 1996 1997 1998 1999 2000 2001 2002 2003 2004
forecast 292.0 294.8 304.2 338.0 373.0 406.9 438.0 469.4 505.8
IMS global sales 337.2 354.0 392.0 430.3 491.8
IMS audited sales 295.9 321.8 364.2 400.6 466.3
sources: Global Pharma Forecasts and IMS

 

generics

– US$ 84bn worth of blockbuster products will lose US patent protection by 2008
– Biologicals worth US$ 15bn in 2003 sales will lose US patent protection by 2007
– Renenues of Top10 generics companies (2002): US$ 10.64 bn

generic biologics are estimated to have reached $30M in 2003, growth is expected to continue at an annual rate of 135% to 2010. By 2010, the market will grow to approximately $12B worldwide (Research & Markets Ltd, 2004)

source: Ernst & Young, Datamonitor

top 20 drug products by sales value (2000) with sales forecast for 2004

download table (pdf file)
source: Nature Reviews Drug Discovery 1, 175-176 (2002)

 

pharma sales through retail pharmacies 01/2003-01/2004

country in US$ m % growth (ref. to US$) % growth at constant exchange rates
world 317,948 14 8
USA 163,157 11 11
Canada 8,862 23 11
Germany 22,748 27 7
France 18,793 27 6
Italy 12,933 22 2
UK 13,177 20 10
Spain 8,980 34 12
Japan (incl. hospitals) 52,825 11 3
Mexico 6,220 2 2
Brazil 4,266 13 13
Argentina 1,594 48 48
source: IMS Strategy Group

pharma sales through retail pharmacies 01/2003-01/2004
according to therapeutic category

therapeutic area in US$ m % growth (ref. to US$) % growth at constant exchange rates
cardiovascular 61,788 15 7
CNS 57,921 19 14
alimentary/ metabolism 46,598 13 7
respiratory 28,185 7 2
anti-infectives 27,025 12 6
muco skeletal 19,972 19 12
genito urinary 17,543 9 4
cytostatics 14,816 18 10
dermatologicals 9,585 11 5
blood agents 10,892 23 14
sensory organs 6,428 15 8
diagnostic agents 5,788 18 10
hormones 5,046 17 9
source: IMS Strategy Group

 

therapeutic categories

Market

Size

Year

Source

WM thrombolytics

US$ 700-800m
US$ 1.2bn

1997
2007

HB, 31 Oct 1996
Decision Resources

WM serum albumin

US$ 1.3bn
US$ 1.5bn

1997
2003

FT, 17 March 1997
P. Reynolds, Biotecnologia

US serum albumin

US$ 1.0bn

2003

Tranxenogen Inc.

WM therapeutic antibodies

US$ 59m
US$ 209m
US$ 323m
US$ 722m
US$ 1336m
US$ 2205m
US$ 2958m
US$ 3567m
US$ 4700m

1995
1996
1997
1998
1999
2000
2001
2002
2003

Frost & Sullivan, BancBoston

WM HepB vaccines

US$ 1.4bn

1999

FAZ

WM human vaccines

US$ 2.9bn
US$ 7.0bn

1994
2000

Frost & Sullivan

growth hormones

EU: US$ 322m
USA: US$ 366m
Japan: US$ 417m

EU: US$ 451m
USA: US$ 417m
Japan: US$ 445m

1998

2004

Frost & Sullivan

WM cell therapies and tissue repair

cell therapies: US$ 14.572bn
tissue engineering: US$ 3.867bn
relevant proteins and peptides: US$ 1.819bn

2007

Business Communications

WM cell culture systems

US$ 125m
US$ 167.2m

1998
2004

Frost & Sullivan (Rep. 3489)

WM lipid hormones

US$ 14.8bn
US$ 22.2bn

1997
2002

Business Communications

WM anti epileptics

US$ 5.2bn

1997

BASF

WM brust cancer therapeutics

US$ 1.5bn
US$ 2.2bn

1997
2007

Decision Resources, Inc.
Tel +32 2 351 4839

WM RA therapies

US$ 1.1bn
US$ 4.3bn

1997
2007

Decision Resources, Inc.
Tel +32 2 351 4839

WM biologics for RA therapy

US$ 4.0bn

2006

Merril Lynch

WM lipid regulating drugs

US$ 7.7bn
US$ 15.0bn

1997
2007

Decision Resources, Inc.
Tel +32 2 351 4839

WM therapies for benign prostate diseases

US$ 900m
US$ 1.3bn

1997
2007

Decision Resources, Inc.
Tel +32 2 351 4839

WM anti-allergicals (non-OTC)

US$ 3bn
US$ 6bn

1999
2005

Richards Communications (Ashland, OR)

WM osteoporosis therapeutics

US$ 2bn
US$ 9bn

1997
2007

Decision Resources, Inc.
Tel +32 2 351 4839

WM advanced drug delivery systems

US$ 32bn
US$ 53bn

1998
2005

Front Line Strategic Management Consulting

WM vitamin C

US$ 600m

1998

Genencor

production of active pharmaceutical ingredients (API)

total

US$ 49.8bn
US$ 77.4bn

2000
2005

GEN, 22,6, 15-03-2002

brand named products

US$ 43.4bn
85%

2000
2005

GEN, 22,6, 15-03-2002

sales of generics

USA

US$ 21.6bn

2005

GEN, 22,6, 15-03-2002

contract production of pharmaceuticals

WM

US$ 14.8bn

1999

GEN, 22,6, 15-03-2002

pharmaceuticals in Germany

Market

Size

Year

Source

number of drugs on the market

2,300

2001

VFA Statistics 2002

drug sales total

€ 32.9bn

sales through pharmacies
€30.1bn
sales thourgh hospitals

€ 2.8bn

exports
– intermediates
– products

€ 19,832.1m
€ 3,416.8m
€ 16,415.3m

imports
– intermediates
– products

€ 12,388.2m
€ 3.200.9m
€ 9,187.3m

Abr.: C&EN = Chemical and Engineering News, FAZ = Frankfurter Allgemeine Zeitung, FT = Financial Times, GEN = Genetic Engineering News, HB = Handelsblatt, VFA = Association of Research-based Pharmaceutical Companies in Germany (VFA)

Hinterlasse eine Antwort

Deine E-Mail-Adresse wird nicht veröffentlicht. Erforderliche Felder sind markiert *

Du kannst folgende HTML-Tags benutzen: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>